BS:PFIZ34 Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; collaborative agreements with Eli Lilly & Company, and Merck KGaA, as well as with Merck and Corning for pharma glass packaging project; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues. It also has research collaboration and license agreements with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads; and Sangamo Therapeutics, Inc. for the development and commercialization of gene therapy products, as well as a research agreement with MindImmune Therapeutics, Inc. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
52.43 BRL
As of 03/22/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Emerging markets
GICS sector: Unknown
Industry: Drug Manufacturers-General
Index country: Brazil
Country of incorporation: Brazil
IPO date: 09/03/2013
Stock exchange: XBSP
Exchange country: Brazil
Market cap: 1,442,286,272,512 BRL
Current dividend yield: 3.31%
Sedol: